Selecta Biosciences Inc (SELB)

NASDAQ
3.460
+0.100(+2.98%)
  • Volume:
    981,402
  • Bid/Ask:
    3.450/3.560
  • Day's Range:
    3.310 - 3.597

SELB Overview

Prev. Close
3.36
Day's Range
3.31-3.597
Revenue
27.65M
Open
3.42
52 wk Range
1.47-5.69
EPS
-0.71
Volume
981,402
Market Cap
391.65M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
233,617
P/E Ratio
-
Beta
0.98
1-Year Change
37.85%
Shares Outstanding
113,193,597
Next Earnings Date
Nov 11, 2021
What is your sentiment on Selecta Biosciences Inc?
or
Market is currently closed. Voting is open during market hours.

Selecta Biosciences Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellSellStrong SellStrong SellSell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Selecta Biosciences Inc Company Profile

Selecta Biosciences Inc Company Profile

Employees
44

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company’s proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Read More
  • someone Who can tell me more about this stock?
    0
    • Buy before january 29
      0
      • Any news?
        0
        • i am an experienced advisor if you want some advises please let me know.   0 0 3 5 9 8 7 9 2 7 7 7 6 6
          0
        • Selecta Biosciences Peter G Traber  Buy 40,000 shares @ $3.24 $129,600.00 12/14/2020
          0
      • Don't wait too long. It's just being shorted and should bounce right back up through the night while all the bags get bought.
        0
        • How can you tell if it's being shorted? Trying to continue learning everything I can about it.
          0
        • Colin Edmonston https://www.tradingview.com/markets/stocks-usa/market-movers-oversold/
          0
      • Sorrento therapeutics is making me big $!
        0
        • After looking at my trend line looks like this would be a good buy at 2.50-2.60.
          1
          • I was able to get back in at 3.13. So doing pretty good. I've still got a lot to learn so I'm not investing much. It's a lot to learn.
            0
            • Hope u got in this morning....still holding long and strong here!
              0
              • I hopped out again at 3.23. Was looking at the gap up and consolidating as my deciding factor. Gonna see what happens tomorrow.
                0
            • Yeah I'm going to wait to see what tomorrow charts looks like.
              0
              • Hope you got back in!
                0
                • You're welcome! Had to jump on the "ibio plane!"
                  0
                  • Wish I woulda stayed in but rather not be too greedy lol. I day traded it yesterday to around 6% gains and hopped out this morning around 2.75. Very new still learning the techniques and developing my strategy!
                    0
                • Short squeeze incoming...
                  0
                  • prepare for a 80 move
                    0
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.